SfN 2024 Free Antibody Promotion

570 products

Showing 385 - 408 of 570 products
View
Western blot analysis of A431 cells treated with calyculin A (100 nM) for 30 min (lane 1 and 2) then treated with lambda phosphatase (lane 3). The blot was probed with anti-Phosphoserine/threonine mouse monoclonal at 1:250 (lane 1) or 1:1000 (lanes 2 & 3).Immunocytochemical labeling of phosphoserine and phosphothreonine in control and calyculin A-treated A431 cells. The cells were labeled with mouse monoclonal anti-Phosphoserine/threonine (PM3801) and rabbit polyclonal anti-Phosphoserine/threonine (PP2551), then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.
Western blot analysis of A431 cells treated with calyculin A (100 nM) for 30 min (lane 1) then treated with lambda phosphatase (lane 2). The blot was probed with anti-Phosphoserine/threonine rabbit polyclonal at 1:1000.Bar graph showing anti-Phosphoserine/threonine (PP2551) binding to a variety of phosphoserine and phosphothreonine peptides, but not control peptide containing unphosphorylated serine or phosphotyrosine.
Western blot of human A431 cells treated with Calyculin A (100 nM) for 30 min. The blot was untreated (lane 1) or treated with lambda phosphatase (lanes 2), then probed with anti-Phosphothreonine (PP4641) at 1:1000.Immunocytochemical labeling of phosphothreonine upregulation in control (left) or calyculin A-treated HeLa cells (right). The cells were labeled with rabbit polyclonal anti-Phosphothreonine (PP4641). The antibody was detected using goat anti-rabbit DyLight® 594.
Bar graph showing rabbit polyclonal anti-Phosphotyrosine (PP2221) binding to a variety of phosphotyrosine containing peptides, but no binding to unphosphorylated peptide (beta-Catenin (a.a. 29-45).Immunocytochemical labeling of phosphotyrosine in control and pervanadate-treated A431 cells. The cells were labeled with rabbit polyclonal anti-Phosphotyrosine (PP2221) and mouse monoclonal anti-Phosphotyrosine (PM3751), then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.
Western blot analysis of PKC isoforms in adult mouse brain lysate. The blot was probed with mouse monoclonal anti-PKC (α,β,γ) clone M499 at 1:250 (lane 1) and 1:1000 (lane 2).
Western blots showing Cos-7 cells transfected with mouse Myc-tagged Plexin-A1 (lanes 1 & 3), neonatal rat brain (lane 2), or Plexin-A1 immunoprecipitated from Myc-tagged Plexin-A1 transfected cells using anti-Myc (lane 4) or anti-Plexin-A1 (PP1301; lane 5). These blots were probed with either the affinity purified anti-Plexin-A1 (PP1301; lanes 1 & 2) or with mouse monoclonal anti-Myc (lanes 3-5).Immunocytochemical double labeling using anti-Myc mouse monoclonal and anti-Plexin-A1 rabbit polyclonal (PP1301) antibodies in Cos-7 cells mock transfected (A,D) or transfected with Myc-tagged mouse Plexin-A1 construct (B,E). The specificity of the binding in E was demonstrated by using Plexin-A1 peptide (PX1305) in the presence of this anti-Plexin-A1 antibody (C,F).
Western blots showing mouse recombinant Plexin-A1 extracellular domain (lanes 1-4). These blots were probed with rabbit polyclonal anti-Plexin-A1 (PP1301) at 1:250 (lane 1) and 1:1000 (lane 2) or with mouse monoclonal anti-Plexin A1 (PM5351) at 1:250 (lane 3) and 1:1000 (lane 4).Immunocytochemical labeling of Plexin A1 in aldehyde fixed and NP-40 permeabilized human NCI-H1299 lung carcinoma cells. The cells were labeled with mouse monoclonal anti-Plexin A1 (PM5351). The antibody was detected using goat anti-mouse DyLight® 594.
Western blots showing mouse brain (lanes 1 & 4), and Cos-7 cells untransfected (lanes 2 & 5) or transfected with mouse myc-tagged Plexin-A1 (lanes 3 & 6). The blots were probed with either affinity purified anti-Plexin-A1 (PP1471); lanes 1-3) or with mouse monoclonal anti-Myc (lanes 4-6).Immunocytochemical double labeling using anti-Myc mouse monoclonal and anti-Plexin-A1 rabbit polyclonal (PP1471) antibodies in Cos-7 cells mock transfected (A,D) or transfected with Myc-tagged mouse Plexin-A1 construct (B,E). The specificity of the binding in E was demonstrated by using Plexin-A1 peptide (PX1475) in the presence of this anti-Plexin-A1 antibody (C,F).
Western blot analysis of Plexin D1 expression in human endothelial cells (HUVEC) (lanes 1-6). The blots were probed with rabbit polyclonals anti-Plexin D1 (Sema domain) (lanes 1 & 2), anti-Plexin D1 (Cytoplasmic domain) (lanes 3 & 4), and anti-Plexin D1 (a.a. 1635-1647) (lanes 5 & 6). Each antibody was used in the presence of their respective blocking peptide (lanes 2, 4 & 6).

Recently Viewed